Imegrimine antioxidant and renal protection

INTERVENTION: The patients will be randomly assigned to the imeglimine and empagliflozin groups and will continue until the 24‐week treatment period. CONDITION: Patients with type 2 diabetes mellitus who have not achieved good glycemic control despite treatment ; Type 2 diabetes PRIMARY OUTCOME: Urinary L‐FABP and 8‐OHdG SECONDARY OUTCOME: Underlying disease, age, sex, height, weight, abdominal circumference, blood pressure, pulse pressure, pulse, BMI, blood count, liver function, renal function, lipids, uric acid, HbA1c level, ABI/baPWV (pulse wave velocity), oxidative stress markers (BAP/d‐ROMs) INCLUSION CRITERIA: 1. age at the time of consent, 20 years or older 2. HbA1c > 6.5% within 8 weeks prior to study drug initiation 3. diet and exercise alone for at least 12 weeks prior to study entry, or taking any single agent (SU, glinide, BG, alpha‐GI, TZD, DPP4 inhibitor) at the same dose for at least 12 weeks prior to study entry 4. gender: any gender 5. inpatient or outpatient: outpatient 6. Patients who can take Imeglimine or Empagliflozin for more than 24 weeks.